Research team led by Dr. Jiri Krupicka of Na Homolce Hospital in Prague, the Czech Republic conducted a double-blind, placebo-controlled, randomized study to the effect of the long-term administration of candesartan - marketed by AstraZeneca and Takeda as Atacand and BioPress respectively - on patients with Hypertrophic cardiomyopathy (HCM).
Generally people with hypertrophic cardiomyopathy display mild symptoms or are completely asymptomatic, up to 1 percent of affected people succumb to sudden cardiac death, often with no previous signs of illness.